These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27183582)

  • 1. Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8.
    Fang C; Qiao Y; Mun SH; Lee MJ; Murata K; Bae S; Zhao B; Park-Min KH; Ivashkiv LB
    J Immunol; 2016 Jun; 196(11):4452-4456. PubMed ID: 27183582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.
    Adamik J; Pulugulla SH; Zhang P; Sun Q; Lontos K; Macar DA; Auron PE; Galson DL
    J Bone Miner Res; 2020 Jan; 35(1):181-195. PubMed ID: 31487061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal High-Fat Diet Promotes Abdominal Aortic Aneurysm Expansion in Adult Offspring by Epigenetic Regulation of IRF8-Mediated Osteoclast-like Macrophage Differentiation.
    Saburi M; Yamada H; Wada N; Motoyama S; Sugimoto T; Kubota H; Miyawaki D; Wakana N; Kami D; Ogata T; Matoba S
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis.
    Gao Y; Ge W
    Cell Death Dis; 2018 Jan; 9(2):33. PubMed ID: 29348610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SENP3 Suppresses Osteoclastogenesis by De-conjugating SUMO2/3 from IRF8 in Bone Marrow-Derived Monocytes.
    Zhang Y; Yang K; Yang J; Lao Y; Deng L; Deng G; Yi J; Sun X; Wang Q
    Cell Rep; 2020 Feb; 30(6):1951-1963.e4. PubMed ID: 32049023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivating Mutation in IRF8 Promotes Osteoclast Transcriptional Programs and Increases Susceptibility to Tooth Root Resorption.
    Thumbigere-Math V; Foster BL; Bachu M; Yoshii H; Brooks SR; Coulter A; Chavez MB; Togi S; Neely AL; Deng Z; Mansky KC; Ozato K; Somerman MJ
    J Bone Miner Res; 2019 Jun; 34(6):1155-1168. PubMed ID: 30840779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Breast Cancer-Induced Osteoclastogenesis by MacroH2A1.2 Involving EZH2-Mediated H3K27me3.
    Kim J; Shin Y; Lee S; Kim M; Punj V; Lu JF; Shin H; Kim K; Ulmer TS; Koh J; Jeong D; An W
    Cell Rep; 2018 Jul; 24(1):224-237. PubMed ID: 29972783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice.
    Dudakovic A; Camilleri ET; Riester SM; Paradise CR; Gluscevic M; O'Toole TM; Thaler R; Evans JM; Yan H; Subramaniam M; Hawse JR; Stein GS; Montecino MA; McGee-Lawrence ME; Westendorf JJ; van Wijnen AJ
    J Biol Chem; 2016 Nov; 291(47):24594-24606. PubMed ID: 27758858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte Subsets With High Osteoclastogenic Potential and Their Epigenetic Regulation Orchestrated by IRF8.
    Das A; Wang X; Kang J; Coulter A; Shetty AC; Bachu M; Brooks SR; Dell'Orso S; Foster BL; Fan X; Ozato K; Somerman MJ; Thumbigere-Math V
    J Bone Miner Res; 2021 Jan; 36(1):199-214. PubMed ID: 32804442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
    Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial loss of Smad7 function impairs bone remodeling, osteogenesis and enhances osteoclastogenesis in mice.
    Li N; Lee WY; Lin SE; Ni M; Zhang T; Huang XR; Lan HY; Li G
    Bone; 2014 Oct; 67():46-55. PubMed ID: 24998669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple pharmacological inhibitors targeting the epigenetic suppressor enhancer of zeste homolog 2 (Ezh2) accelerate osteoblast differentiation.
    Galvan ML; Paradise CR; Kubrova E; Jerez S; Khani F; Thaler R; Dudakovic A; van Wijnen AJ
    Bone; 2021 Sep; 150():115993. PubMed ID: 33940225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation.
    Park-Min KH; Lim E; Lee MJ; Park SH; Giannopoulou E; Yarilina A; van der Meulen M; Zhao B; Smithers N; Witherington J; Lee K; Tak PP; Prinjha RK; Ivashkiv LB
    Nat Commun; 2014 Nov; 5():5418. PubMed ID: 25391636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of IGF-I signaling in regulating osteoclastogenesis.
    Wang Y; Nishida S; Elalieh HZ; Long RK; Halloran BP; Bikle DD
    J Bone Miner Res; 2006 Sep; 21(9):1350-8. PubMed ID: 16939393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway.
    Nishikawa K; Iwamoto Y; Kobayashi Y; Katsuoka F; Kawaguchi S; Tsujita T; Nakamura T; Kato S; Yamamoto M; Takayanagi H; Ishii M
    Nat Med; 2015 Mar; 21(3):281-7. PubMed ID: 25706873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
    Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
    Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Suppressive effects for osteoclastogenesis regulated by RANKL signal].
    Miyauchi Y; Miyamoto T
    Clin Calcium; 2011 Aug; 21(8):1141-7. PubMed ID: 21814018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.